Did Biocardia beat or miss consensus estimates last quarter?

What is Biocardia's latest dividend and current dividend yield?

What were the key takeaways from Biocardia's earnings call?

What factors drove the changes in Biocardia's revenue and profit?

What is the revenue and EPS growth rate for Biocardia year over year?

What were the key takeaways from Biocardia’s earnings call?

What guidance did Biocardia's management provide for the next earnings period?

What is the market's earnings forecast for Biocardia next quarter?

- **Clinical Milestones**: CardiAmp HF II trial enrolling at four centers; Japan PMDA consultations and FDA meeting in Q4 2025. BCDA02 CMI data shows 80-second exercise improvement in five patients.
- **Financial Stability**: $5.3 million cash runway to Q2 2026; no immediate funding needs. R&D expenses up 0.5% YoY due to trial expansion.
- **Regulatory Focus**: Helix system FDA submission Q4 2025; potential Japan approvals for CardiAmp HF and allogeneic stem cells.
- **Partnerships & Innovation**: Heart 3D fusion imaging with CARTech for enhanced delivery; NIH funding for BCDA03 trial.

**【CEO Summary Section】**
- **CardiAmp Cell Therapy Progress**: FDA breakthrough designation for ischemic heart failure; three clinical trials show promise. PMDA consultations in Japan for potential approval, with FDA meeting planned for Q4 2025.
- **CardiAmp HF II Trial**: 250-patient phase III trial enrolling at four centers, using advanced cell analysis for dosing. Medicare reimbursement for all patients. Long-term follow-up data positive, with no safety issues.
- **BCDA02 (Chronic Myocardial Ischemia)**: Open-label rolling cohort of five patients shows 80-second increase in exercise tolerance and 82% reduction in angina episodes. Results being prepared for publication.
- **BCDA03 (Allogeneic Stem Cells)**: Phase I-II trial with 39 patients; seeking NIH funding for completion, expected in Q1 2026. Potential conditional approval in Japan.
- **Helix Delivery System**: FDA 510(k) submission planned for Q4 2025. Integration with heart 3D fusion imaging for enhanced delivery.

**【CFO Financial Commentary】**
- **Q3 2025 Financials**: R&D expenses $936,000 (up 0.5% YoY) due to HF II trial and regulatory activities. SG&A $0.6 million (down 25% YoY) from lower compensation. Net loss $1.5 million, cash $5.3 million, providing runway to Q2 2026.
- **Cash Position**: $6 million from September financing and ATM sales. No immediate need for additional funding.

**【Q&A Highlights】**
- **CMI Data Clarity**: Five-patient rolling cohort shows significant improvement; trial design includes Hawthorne effect mitigation (1-month observation period).
- **Enrollment Challenges**: Resource constraints and site startup costs; no safety or efficacy hurdles. Enrollment expected to accelerate post-regulatory clarity.
- **Japan and FDA Strategy**: PMDA consultations focus on existing data sufficiency. FDA meeting to discuss approvability based on phase II/III results.
- **Funding for BCDA03**: High probability of NIH grant in Q1 2026, enabling trial completion without dilution.

BioCardia, Inc. (BCDA) Q3 2025 Earnings Call Transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

BCDA

BCDA fundamentals

You can ask Aime